Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant human bone morphogenic protein-2 in fracture care.

Alan L Jones1

  • 1Baylor University Medical Center at Dallas, Dallas, TX 75246-1800, USA. AlanJ@BaylorHealth.edu

Journal of Orthopaedic Trauma
|February 16, 2006
PubMed
Summary

Recombinant human bone morphogenic protein-2 (rhBMP-2) effectively treats open tibial fractures. Clinical trials confirm its safety and efficacy, supporting its use in fracture repair and demonstrating a positive economic impact.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intrawound Tobramycin Plus Vancomycin to Prevent Surgical Site Infection in Tibial Fractures: The TOBRA Randomized Clinical Trial.

JAMA·2026
Same author

The Effect of Resident Involvement in Hip Fracture Surgery: An Analysis of a Single Institution Before and After the Addition of an Orthopaedic Surgical Residency.

The Journal of the American Academy of Orthopaedic Surgeons·2023
Same author

Relation of tranexamic acid therapy to length of stay in the hip fracture population.

Proceedings (Baylor University. Medical Center)·2022
Same author

Relation of mobilization after hip fractures on day of surgery to length of stay.

Proceedings (Baylor University. Medical Center)·2022
Same author

A Community Orthopaedic Residency Approach to Education and Training During the COVID-19 Pandemic.

Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews·2021
Same author

Relation of length of stay and other hospital variables to posttraumatic stress disorder and depression after orthopedic trauma.

Proceedings (Baylor University. Medical Center)·2021

Area of Science:

  • Orthopedics
  • Biomaterials
  • Regenerative Medicine

Background:

  • Recombinant human bone morphogenic protein-2 (rhBMP-2) is an osteoinductive protein.
  • rhBMP-2 is available for acute treatment of open tibial fractures.
  • Preclinical and clinical data support rhBMP-2's role in fracture care.

Purpose of the Study:

  • To summarize data from two randomized controlled clinical trials on rhBMP-2 for open tibial shaft fractures and tibial fractures with bone defects.
  • To evaluate the safety and efficacy of rhBMP-2 in these patient populations.
  • To present an economic analysis of rhBMP-2 from hospital and payor perspectives.

Main Methods:

  • Review of two randomized controlled clinical trials.
  • Analysis of safety and efficacy data for rhBMP-2 treatment.

Related Experiment Videos

  • Economic impact assessment from healthcare system viewpoints.

    • Main Results:

    • Clinical trial data support the safety and efficacy of rhBMP-2 in treating open tibial fractures and fractures with bone defects.
    • Economic analysis indicates a favorable cost impact for hospitals and payors.
    • rhBMP-2 demonstrates a significant role in fracture management.

    Conclusions:

    • rhBMP-2 is a safe and effective treatment option for open tibial fractures and tibial fractures with bone defects.
    • The use of rhBMP-2 presents a positive economic value in fracture care.
    • Further integration of rhBMP-2 in orthopedic practice is warranted based on clinical and economic data.